TITLE

Tecfidera captures nearly half of MS market in the USA

PUB. DATE
December 2014
SOURCE
PharmacoEconomics & Outcomes News;Dec2014, Vol. 717 Issue 1, p40
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that the oral disease-modifying therapy (DMT) for multiple sclerosis (MS) from Biogen Idec called Tecfidera has captured nearly 50 percent of the second-line share of newly-diagnosed MS patients, according to a media release from Decision Resources Group.
ACCESSION #
100303105

 

Related Articles

  • Biogen announces new approach for treatment of multiple sclerosis.  // PharmaWatch: CNS;Aug2011, Vol. 10 Issue 8, p7 

    The article reports on the approach to be implemented by Biogen Idec Inc. for the treatment of patients with multiple sclerosis.

  • Tecfidera to Treat MS.  // Monthly Prescribing Reference;May2013, Vol. 29 Issue 5, pA-27 

    The article informs that the dimethyl fumarate capsules Tecfidera from Biogen Idec Inc. has been approved for the oral treatment of multiple sclerosis (MS).

  • Big expectations for Biogen's small MS drug.  // Nature Reviews Drug Discovery;May2013, Vol. 12 Issue 5, p333 

    The article reports on the dimethyl fumarate (BG-12), a drug developed by the pharmaceutical firm Biogen Idec for the treatment of relapsing-remitting multiple sclerosis (RRMS) that was approved by the European and U.S. legislators.

  • Biogen's strong quarter eclipsed by patient death. McCaffrey, Kevin // Medical Marketing & Media;Dec2014, Vol. 49 Issue 12, p16 

    The article reports that the strong third quarter sales of the biotechnology company Biogen Idec Inc. has been clouded by the death of a patient taking the Tecfidera multiple sclerosis treatment.

  • Biogen. Investor's Business Daily // Investors Business Daily;9/10/2015, pA02 

    The article reports that American biotechnology firm Biogen Inc. has licensed the MT-1303 multiple-sclerosis drug candidate from Japanese pharmaceutical firm Mitsubishi Tanabe Pharma Corp., noting that its shares in the U.S. has declined as of September 10, 2015.

  • EMEA Finds More Tysabri PMLs.  // Bioworld Week;11/2/2009, Vol. 17 Issue 44, p2 

    The article reports on the decrease in shares of Biogen Idec Inc. and partner Elan Corp. PLC by 3.42 U.S. dollars, or 7 percent, to close at 43.81 dollars on October 23, 2009. Their shares have declined after the number of progressive multifocal leukoencephalopathy (PML) cases linked to multiple...

  • Biogen Idec Plays On MS Drug Strengths. Alan R. Elliott // Investors Business Daily;1/6/2014, pB02 

    The article features Biogen Idec Inc., noted to be the leader in shifting multiple sclerosis treatments from injectables and infused drugs to oral pills. It highlights the company's Tecfidera, which has received wide attention due to comparatively moderate side effects. An overview of Tecfidera...

  • NICE recommends dimethyl fumarate for MS . . .  // PharmacoEconomics & Outcomes News;Sep2014, Vol. 711 Issue 1, p36 

    The article reports on the recommendation of the National Institute for Health and Care Excellence (NICE) in Great Britain that dimethyl fumarate is an effective treatment for multiple sclerosis. It mentions that dimethyl fumarate is a drug developed by the Biogen Idec Inc., a global...

  • Biogen Idee and Acorda to Develop and Commercialize MS Therapy Fampridine-SR in Markets Outside the US.  // BioPharm International;Aug2009, Vol. 22 Issue 8, p16 

    The article reports on the exclusive collaboration and license agreement between Biogen Idec Inc. and Acorda Therapeutics Inc. to develop and commercialize Fampridine-SR, a multiple sclerosis therapy. Moreover the company also entered into a related supply agreement. Biogen Idec will...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics